Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | BCDIN3D | Q7Z5W3 | 11/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911404 | 0.92 | BCDIN3D (0.41) | FLT3SYKCCNE2CCNA2CCNE1 | |
| SCHEMBL2912867 | 0.92 | FLT3 (0.46) | FLT3SYKCCNE2CCNA2CCNE1 | |
| SCHEMBL2910335 | 0.92 | CCNE2 (0.41) | FLT3SYKCCNE2CCNA2CCNE1 | |
| SCHEMBL2910855 | 0.91 | FLT3 (0.46) | FLT3CCNE1CDK2BCDIN3D | |
| SCHEMBL2912469 | 0.88 | SYK (0.38) | SYKCCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL2913019 | 0.87 | CDK5 (0.35) | SYKCCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL2912676 | 0.87 | BCDIN3D (0.37) | FLT3SYKCCNE2CCNA2CCNE1 | |
| SCHEMBL2910096 | 0.85 | CLK1 (0.40) | FLT3SYKBCDIN3DMAPK1 | |
| SCHEMBL2911109 | 0.85 | CDK2 (0.39) | CCNE2CCNA2CCNE1CDK2CCNA1 | |
| SCHEMBL2912745 | 0.84 | CDK1 (0.44) | SYKCCNE2CCNA2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1348707-B1 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | USTAV EX BOTAN AV CR V V I I O (CZ) | 2010-08-25 | — | — | EP | disclosed |
| US-7745450-B2 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | INSTITUTE OF EXPERIMENTAL BOTANY (CZ) | 2010-06-29 | — | — | US | disclosed |
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | USTAV EXPERIMENTALNI BOTANIKY AV CR (INSTITUTE OF EXPERIMENTAL BOTANY ACADEMY OF | 2005-04-14 | — | — | US | disclosed |
| WO-2003082872-A1 | NOVEL PYRAZOLO[4,3-D]PYRIMIDINES, PROCESSES FOR THEIR PREPARATION AND METHODS FOR THERAPY | USTAV EXPERIMENTALNI BOTANIKY AV CR (INSTITUTE OF EXPERIMENTAL BOTANY ACADEMY OF SCIENCES OF THE CZECH REPUBLIC) (CZ) | 2003-10-09 | — | — | WO | disclosed |
| EP-1348707-A1 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | Ustav Experimentalni Botaniky AV CR (Institute of Experimental Botany Academy of Sciences of the Czech Republic) (CZ) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | CBR3, DHFR, AKR1C3 | FLT3 179/4885SYK 2080/4885CCNE2 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.